Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Cameron

Showing results (1561-1570 of 1,688) with videos related to

Pageof 169
Sort By:
The Lancet. Oncology|May 16, 2015
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trialHelena M Earl, Louise Hiller, Janet A Dunn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2017
Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trialH R Ali, A Dariush, J Thomas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2017
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis TrialH M Earl, L Hiller, J A Dunn, et al.
Digestive Diseases and Sciences|February 17, 2025
Histologic Response or Endoscopic Normalization After Initial Treatment for Eosinophilic Esophagitis in Children Leads to Less Fibrostenosis over Long-Term Follow-UpHannah L Thel, Stephanie A Borinsky, Sean S LaFata, et al.
Nature Chemistry|January 3, 2025
Four-electron reduction of benzene by a samarium(II)-alkyl without the addition of external reducing agentsGeorgia M Richardson, Thayalan Rajeshkumar, Finlay M Burke, et al.
Gastro Hep Advances|September 22, 2025
Weight Gain Is Associated With Decreased Treatment Response to Dietary Therapy in Adults With Eosinophilic EsophagitisStephanie A Borinsky, Sean S LaFata, Timothy S Gee, et al.
Lancet (London, England)|February 1, 2025
Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trialJanet A Dunn, Peter Donnelly, Nada Elbeltagi, et al.
Physical Review Letters|May 21, 2010
Weak superconducting pairing and a single isotropic energy gap in stoichiometric LiFeAsD S Inosov, J S White, D V Evtushinsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2014
Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01)Evandro de Azambuja, Marion J Procter, Dirk J van Veldhuisen, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|May 12, 2025
Endoscopic response to topical steroids is associated with a need for fewer future esophageal dilationsTimothy S Gee, Sean S LaFata, Hannah L Thel, et al.
Pageof 169

Showing results (1561-1570 of 1,688) with videos related to

Sort By:
Pageof 169
The Lancet. Oncology|May 16, 2015
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trialHelena M Earl, Louise Hiller, Janet A Dunn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2017
Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trialH R Ali, A Dariush, J Thomas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2017
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis TrialH M Earl, L Hiller, J A Dunn, et al.
Digestive Diseases and Sciences|February 17, 2025
Histologic Response or Endoscopic Normalization After Initial Treatment for Eosinophilic Esophagitis in Children Leads to Less Fibrostenosis over Long-Term Follow-UpHannah L Thel, Stephanie A Borinsky, Sean S LaFata, et al.
Nature Chemistry|January 3, 2025
Four-electron reduction of benzene by a samarium(II)-alkyl without the addition of external reducing agentsGeorgia M Richardson, Thayalan Rajeshkumar, Finlay M Burke, et al.
Gastro Hep Advances|September 22, 2025
Weight Gain Is Associated With Decreased Treatment Response to Dietary Therapy in Adults With Eosinophilic EsophagitisStephanie A Borinsky, Sean S LaFata, Timothy S Gee, et al.
Lancet (London, England)|February 1, 2025
Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trialJanet A Dunn, Peter Donnelly, Nada Elbeltagi, et al.
Physical Review Letters|May 21, 2010
Weak superconducting pairing and a single isotropic energy gap in stoichiometric LiFeAsD S Inosov, J S White, D V Evtushinsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2014
Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01)Evandro de Azambuja, Marion J Procter, Dirk J van Veldhuisen, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|May 12, 2025
Endoscopic response to topical steroids is associated with a need for fewer future esophageal dilationsTimothy S Gee, Sean S LaFata, Hannah L Thel, et al.
Pageof 169